Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs
Atrial fibrillation (AF) is one of the most frequent causes of stroke. Secondary prophylaxis by oral anticoagulants (OACs) is recommended after stroke in patients with AF. For decades, vitamin-K antagonists (VKAs) were the only available drugs for OAC. In the last years, non-vitamin K antagonist oral anticoagulants (NOACs) like dabigatran, rivaroxaban, apixaban or edoxaban have been introduced as OAC drugs for patients with AF or venous thromboembolism, based on large randomized trials, and their use is recommended by various guidelines.
Source: Epilepsy Research - Category: Neurology Authors: Claudia St öllberger, Josef Finsterer Tags: Short communication Source Type: research
More News: Atrial Fibrillation | Epilepsy | Neurology | Pradaxa | Stroke | Thrombosis | Vitamin K | Vitamins